A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in korean patients with hypercholesterolemia

Park, Sungha; Kang, Hyun–Jae; Rim, Se Joong; Ha, Jong Won; Oh, Byung Hee; Chung, Namsik; Cho, Seung Yun

doi:10.1016/j.clinthera.2005.07.007

Cited by 49 publications

(48 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with previous reports, the change in TG levels in this study was small. Park et al suggested a 30% reduction in levels of TG among patients treated with pitavastatin 2 mg 29) . In contrast, the reduction produced by pitavastatin 1 mg was small (8%) 30) .…”

Section: Triglyceride and Statinmentioning

confidence: 99%

Efficacy of a Low Dose of Pitavastatin Compared with Atorvastatin in Primary Hyperlipidemia: Results of a 12-week, open label study

Yoshitomi¹,

Ishii

Kaneki³

et al. 2006

JAT

View full text Add to dashboard Cite

Section: Triglyceride and Statinmentioning

confidence: 99%

Efficacy of a Low Dose of Pitavastatin Compared with Atorvastatin in Primary Hyperlipidemia: Results of a 12-week, open label study

Yoshitomi¹,

Ishii

Kaneki³

et al. 2006

JAT

View full text Add to dashboard Cite

“…59 The percent change of the serum LDL-C was -38.2% in the pitavastatin group and -39.4% in the simvastatin group, with no significant difference between the two groups. The percent change of the serum TG among patients with baseline TG values higher than 150 mg/dL was -29.8% in the pitavastatin group and -17.4%, in the simvastatin group.…”

Section: Study In Patients With Type 2 Diabetesmentioning

confidence: 99%

“…For example, atorvastatin was found to be associated with a higher risk of musculoskeletal adverse events, including elevation of the serum CK, as compared with pitavastatin in routine clinical practice in Japan (atorvastatin 144/4805, pitavastatin 154/7930; risk ratio 1.54, confidence interval 1.23 to 1.93; P = 0.0001 by the Mann-Whitney U test), 58 and in the comparative study with simvastatin conducted in Korea, 59 greater than 2-fold elevations over the upper limit of normal of the serum CK were observed in 3.8% (2/52) of pitavastatin-treated patients and 9.8% (5/51) of simvastatin-treated patients, although the difference between the two groups was not ststistically significantre.…”

Section: Musculoskeletal Adverse Eventsmentioning

confidence: 99%

Pitavastatin in the Management of Hypercholesterolemia

Nomura

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Abstract:Pitavastatin is an HMG-CoA reductase inhibitor that significantly reduces the plasma levels of total cholesterol, LDL-C and triglycerides, while also causing modest elevation of the plasma high-density cholesterol (HDL-C) level. This statin is minimally metabolized by the cytochrome P-450 (CYP) isozymes; it is glucuronized and converted to the inactive lactone form, which is also minimally metabolized by human hepatic microsomes; therefore, it is associated with a low frequency of drug interactions. Pitavastatin has also been shown to have various pleiotropic effects on platelets, monocytes/macrophages and endothelial cells. In addition, a new effect of pitavastatin of increasing the serum for adiponectin level has been reported recently. Pitavastatin has been reported to be associated with a lower frequency of adverse drug effects such as hepatic dysfunction and rhabdomyolysis, therefore, it may be judged as one of the safer among the strong statins. Several clinical trials of pitavastatin have been conducted. At present, its evaluation in actual clinical use by clinicians around the world is underway. Pitavastatin is an effective and safe drug for patients with hypercholesterolemia.

show abstract

“…7,8,24,28,33,34 The LIVES study showed that pitavastatin produced a sustained increase of the serum HDL-C for two years (LIVES study subgroup analysis 31 ). The mean change of the serum HDL-C at the end of two years was 5.9%.…”

Section: -33mentioning

confidence: 99%

“…[6][7][8] Pitavastatin lowered the serum TG by 22% to 30% in patients with baseline serum TG levels of 150 mg/dL or more. 23,24,28 Several studies have consistently demonstrated that pitavastatin produces strong and sustained elevation of the serum HDL-C.…”

mentioning

confidence: 99%

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

Saitō

2011

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Pitavastatin is one of the most effective treatment agents for lowering serum low-density lipoprotein cholesterol (LDL-C) levels. Because pitavastatin is scarcely metabolized, the risk of drug-drug interactions during multidrug therapy is low, and the LDL-C target is achieved in the majority of patients. The incidence of adverse events associated with pitavastatin treatment has so far been comparable to or lower than that associated with other statins, and glucose metabolism is not affected by the drug. Pitavastatin promotes plaque regression and improves the plaque composition in patients with acute coronary syndrome. The serum level of high-density lipoprotein cholesterol (HDL-C) during treatment with pitavastatin was demonstrated to be inversely associated with the incidence of cardiovascular events. Because of its effective and sustained action to increase HDL-C, pitavastatin is expected to contribute to the prevention of cardiovascular events, in addition to its potent LDL-C lowering effect, especially in patients with low serum HDL-C levels.

show abstract

A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in korean patients with hypercholesterolemia

Cited by 49 publications

References 21 publications

Efficacy of a Low Dose of Pitavastatin Compared with Atorvastatin in Primary Hyperlipidemia: Results of a 12-week, open label study

Efficacy of a Low Dose of Pitavastatin Compared with Atorvastatin in Primary Hyperlipidemia: Results of a 12-week, open label study

Pitavastatin in the Management of Hypercholesterolemia

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

Contact Info

Product

Resources

About